Trial
NCT03003728
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Arkansas
Collaborators
Bristol-Myers Squibb; Altor BioScience
Condition
Multiple Myeloma
Intervention
Elotuzumab
Why stopped
Withdrawal of study support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-10